Research on Traditional Chinese Medicine (TCM) Clinical Treatment of the Acute Episode of Bronchial Asthma.

Summary

Bronchial asthma is a common disease and frequently encountered disease of respiratory apparatus. It has very complex mechanism and multiple inducing factors. This study will focus on a new Chinese therapy on Bronchial asthma, analyzing the treatment mechanism of internal and external use, based on Traditional Chinese Medicine (TCM) theory and clinical practice. The study will also investigate the efficacy of the Chinese drugs and treatments on Bronchial asthma, and provide an effective therapy for this disease.

Conditions

• Bronchial Asthma

Interventions

OTHER

warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum

warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

OTHER

clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum

clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

OTHER

securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum

securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

DRUG

Theophylline Sustained-release Tablets and budesonide suspension

Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day

Sponsors & Collaborators

• Shenyang Huanggu District Central Hospital

  collaborator UNKNOWN

• Benxi City hospital of Chinese medicine

  collaborator OTHER

• Anshan Central Hospital

  collaborator OTHER

• Liaoning University of Traditional Chinese Medicine

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-12-31

Primary Completion

2011-01-31

Completion

2011-02-28